Robert J. Motzer, MD, on Research Areas of Focus in Renal Cell Carcinoma
The medical oncologist at Memorial Sloan Kettering Cancer Center discussed areas of research in renal cell carcinoma that he thinks should be further explored.
In an interview with CancerNetwork®, Robert J. Motzer, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, highlighted areas of research within renal cell carcinoma (RCC) which he believes should be studied further.
Transcription:
I think we’ve made tremendous headway with [immuno-oncology] combinations. I’m hoping that some of the drugs with novel mechanism of actions like [belzutifan; MK-6482], will bear fruit and advance our therapeutic options. And I think the other area that really needs to be explored is a better look and a deep dive into the underlying tumor biology and why some patients respond to 1 medication and some respond to another. Are there different targets that we can identify within the tumors? That’'\s an area now that really needs to be explored.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
